Bogart Wealth LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

Bogart Wealth LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,253 shares of the company’s stock after acquiring an additional 2,692 shares during the period. Bogart Wealth LLC’s holdings in Zoetis were worth $5,744,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Pensionfund Sabic grew its holdings in shares of Zoetis by 55.6% during the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after purchasing an additional 4,000 shares during the period. PFW Advisors LLC acquired a new position in Zoetis during the fourth quarter valued at approximately $1,764,000. JPMorgan Chase & Co. grew its stake in Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the period. Simplify Asset Management Inc. acquired a new stake in shares of Zoetis in the third quarter worth $11,684,000. Finally, Nordea Investment Management AB increased its position in shares of Zoetis by 38.3% in the fourth quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock worth $336,266,000 after acquiring an additional 572,511 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ZTS shares. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Piper Sandler reduced their price objective on Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday. Morgan Stanley lowered their target price on Zoetis from $248.00 to $243.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Finally, UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $214.00.

Zoetis Stock Performance

Shares of ZTS opened at $165.28 on Friday. The firm has a market cap of $74.57 billion, a price-to-earnings ratio of 31.07, a PEG ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The business’s 50 day moving average is $169.08 and its two-hundred day moving average is $179.08. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. Analysts forecast that Zoetis Inc. will post 5.9 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.